Skip to main content

Drug Interactions between Prilosec and vorasidenib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

omeprazole vorasidenib

Applies to: Prilosec (omeprazole) and vorasidenib

GENERALLY AVOID: Concomitant use with inducers of CYP450 1A2 may decrease the plasma concentrations and anti-tumor effects of vorasidenib, which is primarily metabolized by the isoenzyme. The moderate CYP450 1A2 inducers, phenytoin or rifampin, are predicted to decrease the steady state peak plasma concentration (Cmax) and systemic exposure (AUC) of vorasidenib by 30% and 40%, respectively.

MANAGEMENT: Concomitant use of vorasidenib with CYP450 1A2 inducers should be avoided.

References (1)
  1. (2024) "Product Information. Voranigo (vorasidenib)." Servier Pharmaceuticals LLC

Drug and food interactions

Moderate

vorasidenib food

Applies to: vorasidenib

GENERALLY AVOID: Due to induction of CYP450 1A2, the isoenzyme primarily responsible for the metabolic clearance of vorasidenib, smoking tobacco during treatment with vorasidenib may decrease its plasma concentrations and anti-tumor effect. Clinical and pharmacokinetic data are currently lacking.

MANAGEMENT: Patient should be advised to avoid smoking tobacco during treatment with vorasidenib because it may reduce efficacy of the therapy.

References (1)
  1. (2024) "Product Information. Voranigo (vorasidenib)." Servier Pharmaceuticals LLC

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer